The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank

James Dale; Caron Paterson; Ann Tierney; Stuart H. Ralston; David M. Reid; Neil Basu; John Harvie; Neil D. McKay; Sarah Saunders; Hilary Wilson; Robin Munro; Ruth Richmond; Derek Baxter; Michael McMahon; John McLaren; Vinod Kumar; Stefan Siebert; Iain McInnes; Duncan Porter

doi:10.1186/s12891-016-1318-y

The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank

James Dale (Lead / Corresponding author), Caron Paterson, Ann Tierney, Stuart H. Ralston, David M. Reid, Neil Basu, John Harvie, Neil D. McKay, Sarah Saunders, Hilary Wilson, Robin Munro, Ruth Richmond, Derek Baxter, Michael McMahon, John McLaren, Vinod Kumar, Stefan Siebert, Iain McInnes, Duncan Porter

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

215 Downloads (Pure)

Abstract

Background: The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate discovery of phenotypic and prognostic biomarkers.

Methods: Demographic and clinical outcome data are collected from newly diagnosed RA/UA patients every 6 months from around Scotland. Health service utilization data is acquired from Information Services Division, NHS National Services Scotland. Plain radiographs of hands and feet are collected at baseline and 12 months. Additional samples of whole blood, plasma, serum and filtered urine are collected at baseline, 6 and 12 months.

Results: Results are available for 1073 patients; at baseline, 76 % were classified as RA and 24 % as UA. Median time from onset to first review was 163 days (IQR97-323). Methotrexate was first-line DMARD for 75 % patients. Disease activity, functional ability and health-related quality of life improved significantly between baseline and 24 months, however the proportion in any employment fell (51 to 38 %, p = 0.0005). 24 % patients reported symptoms of anxiety and/or depression at baseline. 35/391 (9 %) patients exhibited rapid radiographic progression after 12 months. The SERA Biobank has accrued 60,612 samples.

Conclusions: In routine care, newly diagnosed RA/UA patients experience significant improvements in disease activity, functional ability and health-related quality of life but have high rates of psychiatric symptoms and declining employment rates. The co-existence of a multi-domain description of phenotype and a comprehensive biobank will facilitate multi-platform translational research to identify predictive markers of phenotype and prognosis.

Original language	English
Article number	461
Pages (from-to)	1-8
Number of pages	8
Journal	BMC Musculoskeletal Disorders
Volume	17
DOIs	https://doi.org/10.1186/s12891-016-1318-y
Publication status	Published - 9 Nov 2016

Access to Document

10.1186/s12891-016-1318-yLicence: CC BY

Final Published Version
© The Author(s). 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Final published version, 620 KBLicence: CC BY

Cite this

Dale, J., Paterson, C., Tierney, A., Ralston, S. H., Reid, D. M., Basu, N., Harvie, J., McKay, N. D., Saunders, S., Wilson, H., Munro, R., Richmond, R., Baxter, D., McMahon, M., McLaren, J., Kumar, V., Siebert, S., McInnes, I., & Porter, D. (2016). The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. BMC Musculoskeletal Disorders, 17, 1-8. Article 461. https://doi.org/10.1186/s12891-016-1318-y

@article{4435484eba184d18b627c3e9fd2f567c,

title = "The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank",

abstract = "Background: The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate discovery of phenotypic and prognostic biomarkers.Methods: Demographic and clinical outcome data are collected from newly diagnosed RA/UA patients every 6 months from around Scotland. Health service utilization data is acquired from Information Services Division, NHS National Services Scotland. Plain radiographs of hands and feet are collected at baseline and 12 months. Additional samples of whole blood, plasma, serum and filtered urine are collected at baseline, 6 and 12 months.Results: Results are available for 1073 patients; at baseline, 76 % were classified as RA and 24 % as UA. Median time from onset to first review was 163 days (IQR97-323). Methotrexate was first-line DMARD for 75 % patients. Disease activity, functional ability and health-related quality of life improved significantly between baseline and 24 months, however the proportion in any employment fell (51 to 38 %, p = 0.0005). 24 % patients reported symptoms of anxiety and/or depression at baseline. 35/391 (9 %) patients exhibited rapid radiographic progression after 12 months. The SERA Biobank has accrued 60,612 samples.Conclusions: In routine care, newly diagnosed RA/UA patients experience significant improvements in disease activity, functional ability and health-related quality of life but have high rates of psychiatric symptoms and declining employment rates. The co-existence of a multi-domain description of phenotype and a comprehensive biobank will facilitate multi-platform translational research to identify predictive markers of phenotype and prognosis.",

author = "James Dale and Caron Paterson and Ann Tierney and Ralston, {Stuart H.} and Reid, {David M.} and Neil Basu and John Harvie and McKay, {Neil D.} and Sarah Saunders and Hilary Wilson and Robin Munro and Ruth Richmond and Derek Baxter and Michael McMahon and John McLaren and Vinod Kumar and Stefan Siebert and Iain McInnes and Duncan Porter",

note = "The SERA study was jointly supported by the Chief Scientist{\textquoteright}s Office Scotland (ETM-40) and Pfizer Ltd.",

year = "2016",

month = nov,

day = "9",

doi = "10.1186/s12891-016-1318-y",

language = "English",

volume = "17",

pages = "1--8",

journal = "BMC Musculoskeletal Disorders",

issn = "1471-2474",

publisher = "Springer Verlag",

}

Dale, J, Paterson, C, Tierney, A, Ralston, SH, Reid, DM, Basu, N, Harvie, J, McKay, ND, Saunders, S, Wilson, H, Munro, R, Richmond, R, Baxter, D, McMahon, M, McLaren, J, Kumar, V, Siebert, S, McInnes, I & Porter, D 2016, 'The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank', BMC Musculoskeletal Disorders, vol. 17, 461, pp. 1-8. https://doi.org/10.1186/s12891-016-1318-y

TY - JOUR

T1 - The Scottish Early Rheumatoid Arthritis (SERA) Study

T2 - an inception cohort and biobank

AU - Dale, James

AU - Paterson, Caron

AU - Tierney, Ann

AU - Ralston, Stuart H.

AU - Reid, David M.

AU - Basu, Neil

AU - Harvie, John

AU - McKay, Neil D.

AU - Saunders, Sarah

AU - Wilson, Hilary

AU - Munro, Robin

AU - Richmond, Ruth

AU - Baxter, Derek

AU - McMahon, Michael

AU - McLaren, John

AU - Kumar, Vinod

AU - Siebert, Stefan

AU - McInnes, Iain

AU - Porter, Duncan

N1 - The SERA study was jointly supported by the Chief Scientist’s Office Scotland (ETM-40) and Pfizer Ltd.

PY - 2016/11/9

Y1 - 2016/11/9

N2 - Background: The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate discovery of phenotypic and prognostic biomarkers.Methods: Demographic and clinical outcome data are collected from newly diagnosed RA/UA patients every 6 months from around Scotland. Health service utilization data is acquired from Information Services Division, NHS National Services Scotland. Plain radiographs of hands and feet are collected at baseline and 12 months. Additional samples of whole blood, plasma, serum and filtered urine are collected at baseline, 6 and 12 months.Results: Results are available for 1073 patients; at baseline, 76 % were classified as RA and 24 % as UA. Median time from onset to first review was 163 days (IQR97-323). Methotrexate was first-line DMARD for 75 % patients. Disease activity, functional ability and health-related quality of life improved significantly between baseline and 24 months, however the proportion in any employment fell (51 to 38 %, p = 0.0005). 24 % patients reported symptoms of anxiety and/or depression at baseline. 35/391 (9 %) patients exhibited rapid radiographic progression after 12 months. The SERA Biobank has accrued 60,612 samples.Conclusions: In routine care, newly diagnosed RA/UA patients experience significant improvements in disease activity, functional ability and health-related quality of life but have high rates of psychiatric symptoms and declining employment rates. The co-existence of a multi-domain description of phenotype and a comprehensive biobank will facilitate multi-platform translational research to identify predictive markers of phenotype and prognosis.

AB - Background: The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate discovery of phenotypic and prognostic biomarkers.Methods: Demographic and clinical outcome data are collected from newly diagnosed RA/UA patients every 6 months from around Scotland. Health service utilization data is acquired from Information Services Division, NHS National Services Scotland. Plain radiographs of hands and feet are collected at baseline and 12 months. Additional samples of whole blood, plasma, serum and filtered urine are collected at baseline, 6 and 12 months.Results: Results are available for 1073 patients; at baseline, 76 % were classified as RA and 24 % as UA. Median time from onset to first review was 163 days (IQR97-323). Methotrexate was first-line DMARD for 75 % patients. Disease activity, functional ability and health-related quality of life improved significantly between baseline and 24 months, however the proportion in any employment fell (51 to 38 %, p = 0.0005). 24 % patients reported symptoms of anxiety and/or depression at baseline. 35/391 (9 %) patients exhibited rapid radiographic progression after 12 months. The SERA Biobank has accrued 60,612 samples.Conclusions: In routine care, newly diagnosed RA/UA patients experience significant improvements in disease activity, functional ability and health-related quality of life but have high rates of psychiatric symptoms and declining employment rates. The co-existence of a multi-domain description of phenotype and a comprehensive biobank will facilitate multi-platform translational research to identify predictive markers of phenotype and prognosis.

U2 - 10.1186/s12891-016-1318-y

DO - 10.1186/s12891-016-1318-y

M3 - Article

C2 - 27829394

SN - 1471-2474

VL - 17

SP - 1

EP - 8

JO - BMC Musculoskeletal Disorders

JF - BMC Musculoskeletal Disorders

M1 - 461

ER -

The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank

Abstract

Access to Document

Fingerprint

Cite this